This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
That is a fair summary of where the discussion has got to.
Post #30 describes the usual case. This is about the unusual one.
SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a pharmacological intervention at that time of publication. It also reported a clear dose response across three doses. The categorical thresholds (people reaching 10%, 15%, 20% loss) got the most attention but read less informatively than the mean weight change.
Somebody will have a better source than mine, and I hope they post it.
Confirming post #32 from a second method, which matters more than confirming it from a second person.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
It is worth stating the boring hypothesis before the interesting one.
I think the Tirzepatide and nausea question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
Post #36 is right about the mechanism and I think understates the practical bit.
Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.
I have kept the units in throughout, for the obvious reason.
Coming back to post #34, because the follow-up matters more than the original answer.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
That is a description of practice, not a recommendation of it.
Where I would push back on the Tirzepatide and nausea consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
Answering the question post #39 raises rather than the one it answers.
Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.
I would want the raw data before agreeing with my own summary of it.
The arithmetic in post #39 is right; the assumption feeding it is the part to check.
Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.
One more caveat and then I will stop qualifying: the sample selected itself.
I had read the opposite somewhere and cannot now find where, which tells me something.
Tirzepatide and nausea has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Everything in post #44 holds. The case it does not cover is the one I have.
Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.
Stating my assumptions rather than smuggling them in.
On storage: published stability data covers the licensed formulation at its licensed concentration. A research preparation reconstituted at home in a different diluent at a different concentration is outside every one of those conditions.
Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.
The short answer was in the first line; everything after is the working.
Building on post #47 rather than restating it.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
The right answer here may simply be that it has not been measured.
What I would tell a new member reading about Tirzepatide and nausea for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
Scoping that to what I have actually seen rather than what I have read.
I have no financial interest in anything named in this thread and I want to say so before I comment on Tirzepatide and nausea, because it is the sort of subject where it matters.
Worth separating two things that post #52 runs together.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
Worth checking against a second source before it gets quoted onward.
Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.
Adding a reference point for Tirzepatide and nausea. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
Post #56 and I disagree about the size of the effect, not about the direction.
Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.
That is all the detail I have. Someone else will have more.
I had written a reply contradicting post #56 and deleted it. Here is what survived.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
This is where my knowledge stops and I would rather mark the edge than blur it.